Adam Berrington1, Natalie Voets1, Sarah J Larkin2, Nick de Pennington2, James Mccullagh3, Khalid Al-Qahtani3, Richard Stacey4, Peter Jezzard1, Stuart Clare1, Christopher J Schofield3, Olaf Ansorge2, Tom Cadoux-Hudson4, Puneet Plaha4, and Uzay E Emir1
1FMRIB Centre, University of Oxford, Oxford, United Kingdom, 2Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom, 3Department of Chemistry, University of Oxford, Oxford, United Kingdom, 4Department of Neurosurgery, University of Oxford, Oxford, United Kingdom
We assess the ability of
semi-LASER to detect 2-hydroxyglutarate (2-HG), a metabolic product of mutation
in the enzyme IDH, in gliomas at 3T and 7T. Robust detection could lead to increased
patient stratification yet is hindered by signal overlap and compartmental
artifacts. We find semi-LASER (TE=110ms), with broadband
adiabatic refocussing, is able to correctly identify IDH-mutants at 3T and 7T in
a sample of six patients. Fitting errors are greatly reduced at 7T and additional
metabolites (GABA, Gly) are detected in some IDH-mutated tumours. We conclude
semi-LASER provides a unique clinical opportunity for 2-HG detection at both 3T
and 7T.
